V

    VivoSim Labs, Inc. (VIVS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.29
    +0.01 (+2.14%)

    Market Cap: $3.90M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    78%(21/27)
    Avg Surprise
    -17620.43%
    Streak
    6 Q
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    Reported Jul 14
    		$-0.25N/AN/ABeat+78.1%
    Mar 26
    Reported May 29
    		$-2.21N/AN/ABeat-152.4%
    Dec 25
    Reported Feb 11
    		$-1.03N/AN/ABeat+54.7%
    Sep 25
    Reported Nov 6
    		$-0.98N/A+57.02%Beat+41.7%
    Jun 25
    Reported Aug 12
    		$-1.14$-2.28+50.00%Beat+58.7%
    Mar 25
    Reported May 30
    		$4.21$-2.28+284.65%Beat+152.4%
    Dec 24
    Reported Feb 19
    		$-2.28$-2.40+5.00%Beat+52.5%
    Sep 24
    Reported Nov 8
    		$-1.68$-2.64+36.36%Beat+69.6%
    Jun 24
    Reported Aug 5
    		$-2.76$-3.96+30.30%Beat+50.0%
    Mar 24
    Reported May 10
    		$-8.04$-5.04-59.52%Miss+21.7%
    Dec 23
    Reported Feb 8
    		$-4.80$-4.92+2.44%Beat-1197.3%
    Sep 23
    Reported Nov 9
    		$-5.52$-5.16-6.98%Miss-1352.6%
    Jun 23
    Reported Aug 10
    		$-5.52$-0.46-1100.00%Miss-1391.9%
    Mar 23
    Reported May 25
    		$-10.27N/AN/ABeat-4567.4%
    Dec 22
    Reported Mar 31
    		$-0.37N/AN/ABeat+7.5%
    Sep 22
    Reported Nov 10
    		$-0.38N/AN/ABeat-31.0%
    Jun 22
    Reported Aug 11
    		$-0.37N/AN/ABeat-8.8%
    Mar 22
    Reported May 26
    		$-0.22N/AN/ABeat+40.5%
    Dec 21
    Reported Mar 31
    		$-0.40N/AN/ABeat+70.6%
    Sep 21
    Reported Nov 4
    		$-0.29N/AN/ABeat+78.7%
    Jun 21
    Reported Aug 5
    		$-0.34N/AN/ABeat-1600.0%
    Mar 21
    Reported May 20
    		$-0.37N/AN/ABeat-1750.0%
    Dec 20
    Reported Mar 31
    		$-1.36N/AN/ABeat+81.1%
    Sep 20
    Reported Nov 5
    		$-1.36$-0.06-2166.67%Miss+88.1%
    Jun 20
    Reported Aug 6
    		$-0.02N/A+66.67%Beat+99.8%
    Mar 20
    Reported Jun 10
    		$-0.02N/A+60.00%Beat+100.0%
    Dec 19
    Reported Feb 11
    		$-7.20$-0.05-14300.00%Miss+50.0%
    Sep 19
    Reported Nov 7
    		$-11.42$-12.00+4.83%Beat+4.8%
    Jun 19
    Reported Aug 8
    		$-12.00$-12.00+0.00%Beat+24.9%
    Mar 19
    Reported May 22
    		$-275.41$-0.06-458916.67%Miss-393342.9%
    Dec 18
    Reported Mar 31
    		$-14.40$-15.60+7.69%Beat+14.3%
    Sep 18
    Reported Nov 8
    		$-12.00$-16.80+28.57%Beat+44.4%
    Jun 18
    Reported Aug 9
    		$-15.98$-19.20+16.77%Beat+29.2%
    Mar 18
    Reported May 31
    		$-0.07$-0.07+0.00%Beat+30.0%
    Dec 17
    Reported Mar 31
    		$-16.80$-21.60+22.22%Beat+22.2%
    Sep 17
    Reported Nov 9
    		$-21.60$-24.00+10.00%Beat+10.0%
    Jun 17
    Reported Aug 9
    		$-22.56$-24.00+6.00%Beat-
    Mar 17
    Reported Jun 7
    		$-0.10N/A+95.35%Beat-
    Dec 16
    Reported Mar 31
    		$-21.60$-22.80+5.26%Beat-
    Sep 16
    Reported Nov 3
    		$-24.00$-26.40+9.09%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.07EV/EBITDA-0.34x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-15328.00%
    ROE-343.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio1.70xQuick Ratio1.70x
    Trading Statistics
    Beta1.47Avg Volume6.25M
    52-Week High$5.3052-Week Low$0.26

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.29
    SMA 20$0.32
    SMA 50$0.57
    SMA 200$1.48
    EMA 10$0.30
    EMA 20$0.34
    EMA 50$0.56
    EMA 200$1.44

    MACD

    Line: -0.07Signal: -0.09Hist: 0.02

    ADX

    ADX: 10.4+DI: 24.5-DI: 22.2

    Aroon & PSAR

    Aroon Up36.0
    Aroon Down64.0
    PSAR$0.40

    Bollinger Bands

    Upper Band$0.41
    Lower Band$0.23
    %B Position5800%(Upper)
    Band Width0.34

    RSI (14-Day)

    Neutral
    32.6

    Momentum Oscillators

    Stoch %K24.5
    Stoch %D17.8
    Williams %R-67.0
    ROC (10d)-8.4%
    Momentum-0.03
    CCI (20d)-65.7
    MFI (14d)17.4

    Volatility Measures

    ATR (14d)$0.05(16.1%)
    StdDev (20d)0.05
    Hist Vol187.6%(High)

    Volume Flow

    VWAP$0.29
    OBV187.4M
    AD Line2.9B
    CMF (20d)0.060

    Volume Metrics

    Avg Vol (20d)6.5M
    Vol Ratio0.1x(Low)
    VWMA (20d)$0.43

    Pivot Points

    R3$0.31
    R2$0.30
    R1$0.29
    Pivot Point$0.29
    S1$0.28
    S2$0.28
    S3$0.27

    Advanced Oscillators

    TSI-38.35
    Ultimate Osc55.0
    KST-393.63

    Financial Data

    QuarterJun 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Revenue$18,000$26,000$28,000$37,000$51,000$26,000$30,000$39,000$29,000$5,000$0$75,000
    Cost of Revenue$0$0$0$0$0$0$1,000$2,000N/A$0$0$0
    Gross Profit$18,000$26,000$28,000$37,000$51,000$26,000$29,000$37,000$29,000$5,000$0$75,000
    Operating Expenses$2.78M$2.78M$2.66M$2.95M$3.21M$2.78M$2.64M$3.42M$3.13M$3.69M$4.12M$4.27M
    R&D$1.13M$1.14M$923,000$1.00M$859,000$1.14M$984,000$1.40M$1.06M$1.43M$1.33M$1.67M
    SG&A$1.65M$1.63M$1.74M$1.95M$2.35M$1.64M$1.65M$2.02M$2.06M$2.25M$2.78M$2.60M
    Operating Income$-2,759,000$-2,750,000$-2,635,000$-2,915,000$-3,154,000$-2,750,000$-2,608,000$-3,386,000$-3,096,000$-3,680,000$-4,115,000$-4,195,000
    Interest Income$28,000$63,000$92,000$76,000$11,000$63,000$59,000$44,000$63,000$76,000$121,000$157,000
    Interest Expense$4,000$4,000$0$4,000$0$4,000$0$0$0$0$0$0
    Income Before Tax$-1,335,000$-2,691,000$-2,543,000$-2,843,000$6.85M$-2,691,000$-2,549,000$-3,342,000$-3,045,000$-3,604,000$-3,994,000$-4,026,000
    Income Tax Expense$3,000$0$2,000$0$0$0$0$2,000$0$0$0$2,000
    Net Income$-1,338,000$-2,691,000$-2,545,000$-2,843,000$6.85M$-2,691,000$-2,549,000$-3,344,000$-3,045,000$-3,604,000$-3,994,000$-4,028,000
    EBITDA$-1,319,000$-2,635,000$-2,484,000$-2,854,000$-3,784,000$-2,716,000$-2,540,000$-3,211,000$-3,037,000$-3,609,000$-4,044,000$-4,116,000
    EBIT$-1,359,000$-2,687,000$-2,543,000$-2,915,000$-3,845,000$-2,750,000$-2,608,000$-3,386,000$-3,108,000$-3,680,000$-4,115,000$-4,183,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VIVS

    News

    VivoSim Labs, INC. SEC Filing (Aug 21, 2026)

    This article reports on an SEC filing by VivoSim Labs, INC. (VIVS) on August 21, 2026. The filing is an ARS type, indicating a low impact and neutral sentiment, and was accepted by the SEC EDGAR system at 04:22 PM EST. The document is available as a PDF, and the article also provides recent news and stock data for VivoSim Labs, including its market cap and industry.

    Stock Titan•8/21/26•
    Bullish

    VivoSim Labs Disclosed Failure to Satisfy a Continued Listing Rule or Standard

    VivoSim Labs (VIVS) has received a notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement for 30 consecutive business days. The company has 180 days, until February 16, 2027, to regain compliance and is considering a reverse stock split. VIVS will continue to trade on the Nasdaq Capital Market.

    TradingView•8/21/26•
    Bearish

    VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum

    VivoSim Labs (NASDAQ: VIVS) is gaining investor attention due to its 3D human tissue models and AI, which aim to identify drug toxicity early in pharmaceutical development. This comes as the FDA supports human-relevant alternatives to animal testing. The company reported high predictive accuracy for its NAMkind™ Liver model and VitroSense™ AI platform, is expanding commercial sales in China, and expects significant revenue growth in fiscal 2027.

    WBOC TV•8/18/26•
    Bullish

    VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum

    VivoSim Labs (NASDAQ: VIVS) is gaining investor attention due to its 3D human tissue models, AI, and New Approach Methodologies (NAMs) that aim to identify drug toxicity early, especially as the FDA promotes human-relevant testing alternatives. The company has reported high predictive accuracy for its NAMkind™ Liver model and VitroSense™ AI platform, and recently made its first commercial NAMkind sales in mainland China. VivoSim Labs is also targeting the antibody-drug conjugate (ADC) market and has strengthened its financial position, reiterating guidance for 500%+ revenue growth in fiscal 2027.

    Barchart.com•8/18/26•
    Bullish

    Warrants keep Esousa, Wachs’ VivoSim Labs (VIVS) stake under 10%

    Esousa Group Holdings LLC and Michael Wachs have reported a 9.9% beneficial ownership in VivoSim Labs (VIVS), holding 319,429 shares of common stock. Despite also owning warrants for an additional 576,542 shares, these are excluded from beneficial ownership due to a limitation preventing their stake from exceeding 9.9%. This disclosure was made in an amended Schedule 13G filing, highlighting their sole voting and dispositive power over the reported shares.

    Stock Titan•8/18/26•
    Neutral

    Frequently Asked Questions About VIVS

    Does VIVS pay dividends?
    VivoSim Labs, Inc. (VIVS) does not currently pay a regular dividend.
    What is VIVS's market cap?
    VivoSim Labs, Inc. (VIVS) has a market capitalization of $3.90M with a current stock price of $0.29.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In